KR20180060542A - Wound dressing with chitosan hydrogel and pdrn and a dressing therefor - Google Patents
Wound dressing with chitosan hydrogel and pdrn and a dressing therefor Download PDFInfo
- Publication number
- KR20180060542A KR20180060542A KR1020160160121A KR20160160121A KR20180060542A KR 20180060542 A KR20180060542 A KR 20180060542A KR 1020160160121 A KR1020160160121 A KR 1020160160121A KR 20160160121 A KR20160160121 A KR 20160160121A KR 20180060542 A KR20180060542 A KR 20180060542A
- Authority
- KR
- South Korea
- Prior art keywords
- pdrn
- wound
- kda
- chitosan hydrogel
- wound dressing
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
본 발명은 창상피복재 및 그 도포제에 관한 것으로, 더욱 상세하게는 키토산하이드로겔 및 폴리데옥시리보뉴클레오타이드(PDRN)을 함유하여 창상부위의 보호, 보습, 세포재생 등의 효능을 가지며, 공기 중 노출 시 응고되는 물질인 니트로셀룰로오스를 이용하여 창상피복재 약물이 창상부위에 유지되면서 오염을 방지하여 창상회복을 극대화 시킬 수 있는 도포제를 제공하는 것이다. The present invention relates to a wound dressing and a coating agent thereof. More particularly, the present invention relates to a wound dressing and a coating agent containing the chitosan hydrogel and the polydeoxyribonucleotide (PDRN) to protect the wound, moisturize and regenerate cells, The object of the present invention is to provide a coating agent capable of preventing contamination and maximizing recovery of wound by using nitrocellulose which is a solidifying material, while keeping the wound dressing drug in the wound region.
세계 여러 곳에서 예지하지 못한 사고로 인해 많은 사람들이 타박상, 찰과상, 자창, 절창, 화상 등과 같은 여러 가지 창상으로 인해 고통을 받고 있다. 여러 종류의 창상들에 따라 치료방법과 치료하는 약품이 다르게 적용되며 크게 겔형, 시트형, 폼형 등의 여러 형태의 창상피복재 제품들이 개발 및 판매되고 있다.Because of unexpected accidents in many parts of the world, many people suffer from various injuries such as bruises, abrasions, blisters, blindness, and burns. Different types of wounds are treated and treated differently, and various types of wound dressing products such as gel, sheet, and foam are developed and sold.
여러 제형 중 겔 형태의 창상피복재 제품은 창상부위의 보습 및 보호에 있어서는 효과적이지만 약물을 단독으로 사용하면 창상부위에 약물이 유지되지 않고 흘러내리는 현상으로 인해 약물의 손실이 발생하고 도포한 약물이 외부로부터 오염되는 등의 문제점이 있어 겔 형태의 약물을 도포한 후 거즈 또는 붕대를 이용하여 문제점들을 보완하고 있으나 거즈의 경우 섬유사이가 너무 넓어 섬유사이로 약물의 일부가 흘러나올 수 있고 약물의 오염을 방지하는데 있어 제한이 있으며, 붕대의 경우는 거즈보다 약물이 흡수되는 양이 적고 약물 오염을 방지하는 역할을 할 수 있으나 창상부위를 감아서 고정을 시키는 점에 있어 더운 날씨에는 땀을 유발하는 점과 창상부위를 압박할 수 있는 문제점을 가지고 있다. 이러한 문제점으로 인해 거즈와 붕대는 도포된 약물이 창상치유 목적으로만 사용하고 있다고는 하기 어려운 점이 많다.Among the various formulations, the gel-type wound dressing product is effective in moisturizing and protecting the wound area, but when the drug is used singly, the drug is not retained on the wound area and the drug is lost due to the phenomenon that the drug is lost, And the problem is solved by using gauze or bandage after the gel type drug is applied. However, in the case of gauze, the space between the fibers is so wide that a part of the drug may flow out between the fibers, In the case of bandages, the amount of drug absorbed is smaller than gauze and it can play a role to prevent drug contamination. However, in the point that the wound is fixed by winding the wound area, It has a problem that it can press the area. Because of these problems, it is difficult to say that gauze and bandages are used only for wound healing purposes.
이러한 문제점들을 보완하기 위해 많은 기업들에서는 시트/폼형태로 이루어져 있는 창상피복재들이 개발되고 있다. 시트형/폼형의 경우는 별도의 거즈 또는 붕대를 이용하지 않는 장점을 가지고 있으나 시트/폼형의 경우 창상부위가 넓을 경우에는 사용이 힘든 점이 있으며, 밴드형의 경우는 접착 물질에 대한 알레르기 반응이 있는 환자들에게는 사용하기 힘들며 제거 시 접착물질이 완전히 제거가 되지 않아 창상부위 주변이 깔끔하지 못한 문제점을 가지고 있다.In order to overcome these problems, many companies have developed wound dressings made of sheet / foam. In case of sheet type / foam type, it is advantageous not to use separate gauze or bandage. However, in case of sheet / foam type, it is difficult to use when wide wound area is used. In case of band type, And the adhesive material is not completely removed at the time of removal, so that the vicinity of the wound area is not clean.
일본에서는 ‘바르는 반창고’라는 제품들이 개발 및 판매되고 있으며 국내에서도 바르는 반창고가 개발 및 판매되고 있다. 바르는 반창고는 약물이 공기 중에 노출 시 응고되어 막을 형성하는 원리를 이용한 제품이며, 약물은 네일아트에 사용하는 브러쉬와 동일한 것으로 도포하게 된다. 브러쉬를 이용하여 반창고 약물을 도포하는 방법으로 인해 창상치유 약물 위에 도포되면 약물이 브러쉬에 의해 일부가 손실되는 현상이 나타나는 문제점이 있다.In Japan, products called 'plastered plaster' are being developed and sold, and a plaster that is applied in Korea is being developed and sold. The applied band-aid is a product using the principle that the drug coagulates when exposed to air to form a film, and the drug is applied in the same manner as the brush used for nail art. There is a problem that a part of the drug is lost by the brush when the drug is applied on the wound healing drug due to the method of applying the band-aid drug using the brush.
현재 판매되고 있는 많은 창상피복재들은 제품의 형태가 다르나 보호, 보습과 같은 효능은 대부분 동일하다. 하지만 동일한 효능이지만 각각 제품들에 있어 큰 차이점은 창상치유의 속도에 있다. 창상치유가 빠르게 진행이 될수록 제품의 사용 횟수가 줄어들고, 세포재생이 늦어질수록 제품사용횟수는 증가하게 된다. 또한 제품사용횟수가 증가하게 되면 약물을 다시 도포함에 있어 외부의 세균으로부터 창상이 감염될 수 있으므로 염증반응의 발생 가능성이 높아지게 되어 창상회복 속도는 감소하게 된다. 상처부위가 치유되면서 삼출액에 의해 염증반응이 일어나게 되며 삼출액을 흡수할 수 있게 창상피복재 제품들은 삼출액이 흡수되도록 개발되고 있으나 완벽하게 삼출액이 흡수될 수 없기 때문에 별도로 염증이 일어나지 않게 약을 복용하거나 주사로 약물을 투여하게 되는 문제점이 있다.Many of the wounds currently on the market are of the same product type, but most of their efficacy, such as protection and moisturizing, is the same. But the same effect, but the biggest difference in each product is the speed of wound healing. As the wound healing progresses rapidly, the frequency of use of the product decreases, and as the cell regeneration becomes slower, the frequency of use of the product increases. In addition, as the use frequency of the product increases, the possibility of inflammation reaction is increased, and the wound recovery rate is decreased because the wound can be infected from external bacteria in reapplying the drug. The wound is healed and the inflammation reaction occurs by the exudate. The wound dressings are developed to absorb the exudate, but since the exudate can not be completely absorbed, There is a problem that the drug is administered.
대한민국 특허 제100847971호는 "상처치료용 키토산 하이드로겔 패치"에 관한 것으로, 수용성키토산을 함유하는 하이드로겔 패드를 절단 지지체가 합지되어 있는 폴리우레탄 필름에 합지시키고, 하이드로겔 층을 이형필름 또는 이형지로 피복한 구조를 갖는 패치를 제공하고 있으나, 이는 앞서도 설명한 바와 같이 넓은 범위에 사용하기에 제한적이고, 움직임 등에 제한이 있는 단점이 있다. Korean Patent No. 100847971 relates to a "patch for chitosan hydrogel gel for wound healing" wherein a hydrogel pad containing water-soluble chitosan is put on a polyurethane film having a cutting support laminated thereon and the hydrogel layer is coated with a release film or release paper A patch having a coated structure is provided. However, as described above, the patch is limited to use in a wide range and has disadvantages such as limited movement.
따라서 창상 보호, 보습, 세포재생을 통합한 새로운 제품 개발이 필요하며 그 제품이 창상에만 효과를 나타내기 위한 드레싱 제품 개발의 필요성이 지속적으로 대두되고 있다.Therefore, it is necessary to develop a new product that integrates wound protection, moisturizing and cell regeneration, and there is a continuing need to develop a dressing product so that the product can be effective only on the wound.
본 발명은 상기와 같은 종래의 문제점을 해결하기 위하여 안출된 것으로, 키토산하이드로겔을 함유하여 창상보호 및 보습의 효능을 가지며, 분리막 공정으로 간단하게 제조된 분자량 300±150kDa의 폴리데옥시리보뉴클레오타이드(PDRN)을 함유하여 탁월한 세포재생능을 가지는 창상피복재를 제공하는 것이며, 동시에 창상부위에 피복재가 도포되어 장시간 약물을 유지하고 오염을 방지하며 산소투과도를 높이고 수축을 최소화할 수 있는 창상피복재 도포제를 제공하는 것이다. Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made keeping in mind the above problems occurring in the prior art, and an object of the present invention is to provide a polydeoxyribonucleotide having a molecular weight of 300 ± 150 kDa, which has chitosan hydrogel, PDRN) to provide a wound dressing material having excellent cell regeneration ability. At the same time, a covering material is applied to the wound area to maintain a drug for a long time, prevent contamination, increase the oxygen permeability and minimize shrinkage. .
본 발명의 목적은 SUMMARY OF THE INVENTION
키토산하이드로겔과 PDRN 및 첨가제로 구성되되, Chitosan hydrogel, PDRN and an additive,
상기 PDRN은 The PDRN
정제되지 않은 PDRN에 증류수를 첨가하는 단계;Adding distilled water to the unpurified PDRN;
500kDa 이하의 PDRN이 여과될 수 있는 막을 통과시키는 1차 정제단계;A first purification step of passing a membrane through which a PDRN of 500 kDa or less can be filtered;
상기 1차 정제된 PDRN에 증류수를 첨가하는 단계;Adding distilled water to the first purified PDRN;
200kDa 이하의 PDRN이 여과될 수 있는 막을 통과시키는 2차 정제단계;A second purification step of passing a membrane through which a PDRN of less than or equal to 200 kDa can be filtered;
상기 2차 정제단계에서 정제되지 않은 PDRN과 불순물을 분리하는 단계;Separating impurities from the PDRN not purified in the second purification step;
를 포함하는 막분리법에 의해 수득되며 분자량이 350±150kDa인 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재를 제공하는 것이다. , And having a molecular weight of 350 + - 150 kDa, which comprises a chitosan hydrogel and a PDRN.
본 발명의 또 다른 목적은 Another object of the present invention is to provide
에탄올과 에틸아세테이트가 혼합된 용액에 니트로셀룰로오스를 용해한 용액을 분사형 도포제로 제공하는 것이다. A solution in which nitrocellulose is dissolved in a solution in which ethanol and ethyl acetate are mixed is provided as a spray-type coating agent.
이하 본 발명을 더욱 상세히 설명하기로 한다. Hereinafter, the present invention will be described in more detail.
본 발명은 The present invention
키토산하이드로겔과 PDRN 및 첨가제로 구성되되, Chitosan hydrogel, PDRN and an additive,
상기 PDRN은 The PDRN
정제되지 않은 PDRN에 증류수를 첨가하는 단계;Adding distilled water to the unpurified PDRN;
500kDa 이하의 PDRN이 여과될 수 있는 막을 통과시키는 1차 정제단계;A first purification step of passing a membrane through which a PDRN of 500 kDa or less can be filtered;
상기 1차 정제된 PDRN에 증류수를 첨가하는 단계;Adding distilled water to the first purified PDRN;
200kDa 이하의 PDRN이 여과될 수 있는 막을 통과시키는 2차 정제단계;A second purification step of passing a membrane through which a PDRN of less than or equal to 200 kDa can be filtered;
상기 2차 정제단계에서 정제되지 않은 PDRN과 불순물을 분리하는 단계;Separating impurities from the PDRN not purified in the second purification step;
를 포함하는 막분리법에 의해 수득되며 분자량이 350±150kDa인 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재를 제공하는 것이다. , And having a molecular weight of 350 + - 150 kDa, which comprises a chitosan hydrogel and a PDRN.
본 발명에 따른 키토산 하이드로겔은 키토산의 성능과 하이드로겔의 성능을 가지도록 하여 창상피복재에 사용되는 것을 특징으로 한다. The chitosan hydrogel according to the present invention is characterized in that the chitosan hydrogel is used as a wound dressing material so as to have chitosan performance and hydrogel performance.
대게, 새우와 같은 갑각류 껍데기로부터 수산화나트륨 염기 처리하면 얻어지는 아래 구조식 1의 "키토산"은 D-글루코사민과 N-아세틸글루코사민으로 이루어진 선형 다당류이다. 키토산은 지혈 및 항균 특성을 가지는 물질이며 급속으로 혈액 응고를 할 수 있는 특징으로 미국에서는 지혈제로 승인을 받았으며 유럽에서는 붕대 및 지혈제로 사용하고 있다. Generally, "chitosan" is a linear polysaccharide composed of D-glucosamine and N-acetylglucosamine, which is obtained by sodium hydroxide treatment from crustacean shells such as shrimp. Chitosan is a substance that has hemostatic and antibacterial properties. It is fast-blooded and has been approved as a hemostatic agent in the United States. It is used as a bandage and hemostatic agent in Europe.
[구조식 1][Structural formula 1]
"하이드로겔"은 다량의 수분을 함유할 수 있는 삼차원 망상 구조를 가지는 고분자 물질이며, 일반적으로 유연한 강도 및 함수율이 커서 생체 조직과 유사한 특성을 나타내므로 의학 혹은 약학 분야에 널리 이용되고 있다. 주로 화상이나 외상의 치료 보조 소재로써, 체내로부터의 수분 누출을 방치하고 삼출액을 흡수하며 외부로부터의 세균 침입 및 감염의 방지를 위해 사용한다.A "hydrogel" is a polymer material having a three-dimensional network structure capable of containing a large amount of water, and is generally widely used in medical or pharmaceutical fields because of its flexibility and strength, It is mainly used as a therapeutic material for burns and trauma, and it is used for absorbing the exudates and for preventing invasion of bacteria and infection from the outside.
본 발명에 따라 제조된 키토산 하이드로겔은 가교제의 첨가없이 자가가교에 의해 만들지며 키토산의 특성인 지혈 효과로 창상이 발생하였을 때 창상부위에서 일부 출혈이 발생하면 그러한 부분은 막아주는 역할을 할 뿐만 아니라 항균 효과로 인해 최초 창상 발생으로 감염된 세균감염에 대한 치료도 동시에 이루어 질 수 있다.The chitosan hydrogel prepared according to the present invention is formed by self-crosslinking without addition of a crosslinking agent. When a wound is formed due to a hemostatic effect, which is a characteristic of chitosan, when a partial bleeding occurs in the wound, Because of the antimicrobial effect, treatment for bacterial infections caused by the initial wound infection can also be performed at the same time.
또한, 하이드로겔의 특성에 의해 추가적인 세균감염으로부터 창상을 보호하며 보습 효과를 얻을 수 있고 삼출액 흡수가 가능하여 창상부위에서 생기는 염증반응이 일어나는 것을 막아주는 역할도 하게 된다. In addition, due to the characteristics of the hydrogel, it is possible to protect the wound from additional bacterial infection, to obtain a moisturizing effect, to absorb the effusion, and to prevent the inflammatory reaction occurring in the wound area from occurring.
본 발명에 따른 폴리데옥리보뉴클레오타이드(PDRN)는 도 1에 도시한 개념도 및 아래의 제조방법에 의해 제조된 것을 특징으로 한다. The polydeoxyribonucleotide (PDRN) according to the present invention is characterized in that it is produced by the conceptual diagram shown in Fig. 1 and the following manufacturing method.
먼저, 정제되지 않은 PDRN을 반응조에 투입하고 여기에 증류수를 첨가한 뒤 500kDa 미만의 PDRN이 여과될 수 있는 멤브레인에 용액을 3 내지 4회 반복 통과시켜 여과하는 1차 정제단계를 거친다. 이때, 정제되지 않은 PDRN 용액은 분해과정을 거쳐 다시 여과하는 단계를 거친다. First, an unpurified PDRN is added to the reaction tank, distilled water is added thereto, and the solution is subjected to a first purification step in which the solution is repeatedly passed through the membrane through which the PDRN of less than 500 kDa can be filtered by repeatedly passing through the solution three to four times. At this time, the unpurified PDRN solution is subjected to a decomposition step and then to filtration again.
그 후, 상기 1차 정제된 PDRN에 다시 증류수를 첨가한 뒤 200kDa 미만의 PDRN이 여과될 수 있는 멤브레인막을 3 내지 4회 반복하여 통과시키는 2차 정제단계를 거친다. 이때, 여과된 200kDa의 PDRN 용액은 별도로 보관을 하며 상기 2차 정제단계에서 정제되지 않은 PDRN과 불순물을 분리하는 단계를 진행하여 분자량 350±150kDa인 PDRN을 수득한다. Thereafter, distilled water is again added to the first purified PDRN, and then a second purification step in which a membrane membrane capable of filtering PDRN of less than 200 kDa is repeatedly passed through the membrane three to four times. At this time, the filtered 200 kDa PDRN solution is stored separately, and in the second purification step, PDRN having a molecular weight of 350 ± 150 kDa is obtained by separating impurities from undissolved PDRN.
PDRN(PolyDeoxyRiboNucleotide)은 DNA복합체, 즉 deoxyribonucleotide 중합체가 포함된 화합물로서 A2 puringergic receptor를 자극하여 특별한 부작용 없이 세포재생에 필요한 활성체로 작용하게 되고, 줄기세포, 섬유아세포, 연골세포 등의 세포 분화를 촉진시키므로 화상이나 만성창상 등에 효과적인 물질이며, 인체의 유전자와의 높은 유사성으로 안전성이 우수하고, VEGF를 활성화하여 부수적인 항염증, 혈전용해, 성장인자 촉진 작용 등의 효능을 가지는 물질이다. PDRN (PolyDeoxyRiboNucleotide) is a compound containing a DNA complex, ie, a deoxyribonucleotide polymer, which stimulates the A2 puringergic receptor to act as an activator for cell regeneration without special side effects, and promotes cell differentiation such as stem cells, fibroblasts and chondrocytes It is a substance effective for burns and chronic wounds. It is highly safe due to its high similarity with human genes, and has an effect of activating VEGF and having an additional anti-inflammatory, thrombolytic and growth factor promoting action.
[ PDRN의 작용 개념도][Operation concept diagram of PDRN]
PDRN은 연어 또는 청어의 정소로부터 추출한 물질로써 100Da에서 1500kDa 까지의 넓은 범위의 분자량을 가지고 있다. 분자량 크기에 따라 용도가 다르므로, 예를 들어 창상피복재와 같은 외형제 제품에 사용하는 경우에는 분자량 약 200 내지 500kDa의 PDRN이 사용되므로, PDRN을 정제하여 분자량별로 분류하는 공정이 필요하다. 정제과정에서 GPC와 같은 column을 사용하게 되며 GPC의 경우는 소량 정제가 가능하나 대량으로 정제할 경우 고가의 장비를 이용하여 PDRN정제를 진행하게 된다. 이러한 고가의 장비로 PDRN 정제과정를 진행하면 공정 비용이 상승하게 되어 크기별로 정제된 PDRN은 비싼 가격에 수급해야 되며 이렇게 정제된 PDRN을 이용하여 제품을 개발하면 제품에 대한 단가가 증가하는 문제가 발생한다.PDRN is a substance extracted from the testes of salmon or herring and has a broad molecular weight ranging from 100 Da to 1500 kDa. Since PDRN having a molecular weight of about 200 to 500 kDa is used when it is used in a cosmetic product such as a wound dressing, for example, it is necessary to purify PDRN and classify it by molecular weight. In the purification process, a column such as GPC is used. In the case of GPC, a small amount of purification can be performed. However, when purified in a large amount, PDRN purification is performed using expensive equipment. When the PDRN purification process is performed with such expensive equipment, the process cost is increased. Therefore, the PDRN purified by size needs to be supplied at an expensive price. If the product is developed using the purified PDRN, there is a problem that the unit price for the product increases .
본 발명에서는 설비가 간단하고 정제방법이 간단한 막분리법에 의해 외형제로 사용할 수 있는 수준의 PDRN 즉, 분자량 350±150kDa인 PDRN을 수득한 바, 성능을 통상적으로 사용하는 고가의 장비에 의해 수득된 동일분자량의 PDRN과 비교하면 아래 표 1과 같다. In the present invention, PDRN having a level that can be used as an external agent by simple membrane separation method with simple facilities and a purification method is obtained, that is, PDRN having a molecular weight of 350 +/- 150 kDa is obtained, and the same Table 1 below compares PDRN of molecular weight.
본 발명에 따른 막분리법에 의한 PDRN 제조방법은 종래의 방법에 비해 제조공정이 간단하고 비용면에서 경제적일 뿐만 아니라, 표 1에서 보여지는 바와 같이 종래의 방법에 의해 정제된 PDRN과 대비할 때 성능에 있어서도 차이가 없다. The PDRN production method according to the present invention is simpler in manufacturing process than the conventional method and is economical in terms of cost. In addition, as shown in Table 1, when compared with PDRN purified by the conventional method, There is no difference.
PDRN은 주로 DNA주사로 활용하고 있으며, DNA주사는 섬유아세포와 콜라겐 등의 성장인자를 자극하여 세포 증식과 치유를 촉진시키는 물질로 타 치료나 주사에 비해 30% 이상 효과가 빠르고 강력하며 효과의 지속기간이 길다. 기존 주사제들의 효능과 안정성을 뛰어 넘을 뿐만 아니라, 염증유발로 인한 통증이 없어 불편함을 덜어주며 인위적인 방법이 아닌 인체 본연의 메커니즘을 통한 균형 있는 재생을 유도함으로 부작용이 없다. 일반적인 통증이나 염증 치료제들과 달리 세포 및 조직의 재생을 돕는 치료제로서 단기간의 증상완화 차원의 일시적인 역할이 아닌 근본적인 치유를 기대할 수 있겠으며 조직 재생의 효과 역시 반감기가 짧은 성장인자들을 공급하는 것이 아니라 유전자 발현의 촉진에 의한 성장인자의 생성을 유도함으로 지속적인 효과를 기대할 수 있다.PDRN is mainly used for DNA injection. DNA injection stimulates growth factors such as fibroblasts and collagen to promote cell proliferation and healing. It is more effective than other treatments or injections by 30% or more, The period is long. Not only does it overcome the efficacy and safety of existing injections, it also relieves discomfort because there is no pain caused by inflammation, and it has no side effects because it induces balanced regeneration through the mechanism of the human body rather than an artificial method. Unlike general pain or inflammation treatments, it is not a transient role of short-term symptom relief as a therapeutic agent to help regenerate cells and tissues, but it is expected that fundamental healing can be expected. The effect of tissue regeneration is not a supply of growth factors with short half- It is possible to expect a continuous effect by inducing the generation of growth factors by promoting expression.
도 2는 본 발명에 따른 키토산하이드로겔과 PDRN을 혼합하여 창상피복재를 제조하는 과정을 나타낸 개념도이다. FIG. 2 is a conceptual view illustrating a process of preparing a wound dressing material by mixing the chitosan hydrogel and PDRN according to the present invention.
본 발명에서는 상기와 같이 제조된 창상피복재를 창상부위에 도포한 후 피복재의 약물이 오랜기간 오염이나 변형 없이 상처부위에 유지되는 것을 도와주는 도포제(또는 드레싱)를 동시에 제공하는 것을 목적으로 한다. The object of the present invention is to provide a coating agent (or a dressing) which helps the drug of the covering material to be kept on the wound area without contamination or deformation for a long time after the wound dressing material as described above is applied to the wound area.
본 발명에 따른 창상피복재 도포제는 분사형 형태로 제공되며 상기 분사형 도포제는 에탄올과 에틸아세테이트가 1:2의 비율로 혼합된 용액에 니트로셀룰로오스를 5 내지 20 중량% 용해한 용액인 것을 특징으로 한다. The coating agent for wound dressing according to the present invention is provided in a spray form, and the spray type coating agent is a solution in which nitrocellulose is dissolved in an amount of 5 to 20 wt% in a solution in which ethanol and ethyl acetate are mixed at a ratio of 1: 2.
본 발명에 따른 분사형 도포제의 경우 도포량은 0.5 내지 2mg/㎠, 도포된 피막의 두께는 0.5 내지 1mm 이하인 것이 바람직하고 산소투과도는 90%이상, 건조속도는 10 내지 20초인 것이 바람직하다.In the case of the spray-type coating agent according to the present invention, the coating amount is preferably 0.5 to 2 mg / cm 2, the thickness of the applied coating is preferably 0.5 to 1 mm or less, the oxygen permeability is preferably 90% or more and the drying speed is preferably 10 to 20 seconds.
종래 바르는 반창고는 상처부위에 바르면 빠르게 응고가 되어 상처부위를 보호하는 역할을 하는 제품이나 이 제품은 작은 상처에는 사용이 용이하나 큰 상처에 사용할 경우 응고가 되면서 막이 수축하게 된다. 이러한 수축으로 인해 상처부위를 압박하여 손상되게 하며 상처치유에 있어 역효과를 줄 수 있다. Conventionally used bandage is a product that acts to protect the wound area by rapidly solidifying when applied to the wound area. However, this product is easy to use for small wound, but when it is used for large wound, the film shrinks as it becomes solidified. Such shrinkage can cause the wound to be damaged by compression, which can adversely affect wound healing.
본 발명에 따른 분사형 도포제는 원재료의 약물이 응고되어 막 수축 현상이 최소화되는 조성물을 제공하는 것으로 창상피복재 약물을 유지시키며 산소투과도를 극대화하여 창상부위 세포에 산소 공급이 원활하게 하여 세포 재생에 기여할 수 있게 된다.The spray-type spraying agent according to the present invention provides a composition in which the drug of the raw material is solidified to minimize the film shrinkage phenomenon, which keeps the wound dressing drug and maximizes the oxygen permeability so as to smoothly supply oxygen to the wound cells, .
도 3은 본 발명에 따른 창상피복재가 창상부위에 부착되고 피복재를 보호하기 위한 분사형 도포제가 도포되는 형상을 나타낸 개념도이다. FIG. 3 is a conceptual diagram showing a shape in which a wound dressing material according to the present invention is applied to a wound region and a spray-type coating agent for protecting a covering material is applied.
본 발명에 따라 제조된 키토산 하이드로겔 및 PDRN을 함유하는 창상피복재는 키토산의 특성인 지혈 효과로 창상이 발생하였을 때 창상부위에서 일부 출혈이 발생하면 그러한 부분은 막아주는 역할을 할 뿐만 아니라 항균 효과로 인해 최초 창상 발생으로 감염된 세균감염에 대한 치료도 동시에 할 수 있는 효과가 있다. 또한, 저렴한 막분리법으로 수득 된 PDRN으로 인하여 세포재생효능을 가져 창상부위의 회복을 증가시키는 효과를 가진다. 나아가, 분사형도포제(또는 드레싱제)는 창상피복재 약품을 창상부위에 유지시켜주면서 약품의 오염을 방지할 수 있는 효과를 가진다. The chitosan hydrogel and the PDRN-containing wound dressing prepared according to the present invention have a hemostatic effect, which is a characteristic of chitosan. When a wound occurs, some bleeding occurs at the wound, It is also effective to treat bacterial infections caused by the initial wound infection. In addition, PDRN obtained by an inexpensive membrane separation method has an effect of enhancing the recovery of the wound region due to cell regeneration efficacy. Furthermore, the spray-type coating agent (or dressing agent) has the effect of preventing contamination of the drug while keeping the wound dressing agent on the wound site.
도 1은 본 발명에 따른 막분리법에 의한 PDRN 제조공정을 나타낸 개념도이고,
도 2는 본 발명에 따른 키토산하이드로겔 및 PDRN으로 구성되는 창상피복재를 제조하는 과정을 나타낸 개념도이고,
도 3은 본 발명에 따른 창상피복재를 창상부위에 부착한 후 분사형 도포제를 도포한 형상을 나타낸 개념도이고,
도 4는 본 발명의 일실시예에 따른 창상피복재를 창상부위에 적용한 경우의 조직재생력을 대비한 그래프이다. 1 is a conceptual view showing a PDRN manufacturing process by a membrane separation method according to the present invention,
FIG. 2 is a conceptual view showing a process for producing a wound dressing comprising chitosan hydrogel and PDRN according to the present invention,
FIG. 3 is a conceptual view showing a shape in which a wound dressing material according to the present invention is applied to a wound region,
FIG. 4 is a graph illustrating a regenerative force of tissue when a wound dressing according to an embodiment of the present invention is applied to a wound region.
이하, 하기 실시예 및 실험예에 의하여 본 발명을 더욱 상세히 설명하고자 한다. 그러나 하기 실시예 및 실험예는 본 발명을 예시하기 위한 것으로 이들만으로 본 발명이 한정적으로 이해되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, the following Examples and Experiments are for illustrative purposes only and are not intended to be construed as limiting the present invention.
실시예Example 1 One
키토산(Chitosan) 2중량%을 1% acetic acid 수용액에 첨가하여 기계식 교반기를 이용하여 600rpm으로 60분간 교반하여 용해시키고, 0.1% sodium hydroxide 수용액을 첨가하여 30분간 추가적으로 교반한다. 30분 뒤, 교반하지 않은 상태로 24시간 실온에 보관 뒤, ethanol에 천천히 첨가하면서 교반하여 석출시킨다. 석출된 hydrogel을 PBS에 용해시킨 뒤, PDRN 1중량% 첨가하여 창상피복재를 제조한다.2% by weight of chitosan was added to 1% acetic acid aqueous solution, and the mixture was stirred for 60 minutes at 600 rpm using a mechanical stirrer. The mixture was further stirred for 30 minutes by adding 0.1% aqueous sodium hydroxide solution. After 30 minutes, it is stored at room temperature for 24 hours without stirring, and then slowly added to ethanol and stirred to precipitate. The precipitated hydrogel was dissolved in PBS, and 1 wt% of PDRN was added to prepare a wound dressing.
비교예Comparative Example 1 One
Chitosan 2중량%를 첨가하여 제조된 chitosan hydrogel을 PBS에 용해시켜 창상피복재를 제조한다.Chitosan hydrogel prepared by adding 2% by weight of chitosan is dissolved in PBS to prepare a wound dressing.
실시예 1 및 비교예 1의 방법에 의해 제조된 창상피복재의 조직재생력을 평가하였다. The tissue regeneration ability of the wound dressing prepared by the method of Example 1 and Comparative Example 1 was evaluated.
조직재생력은 쥐의 등에 지름 2cm의 결손 상처를 형성시킨 후 각각 시간에 따른 상처의 크기변화를 확인하며 기간별로 이미지를 촬영한 후 이미지 분석 프로그램을 이용하여 상처의 크기 변화를 하기 식1과 같이 계산한 값의 평균치를 도 4에 나타내었다.The tissue regeneration was performed by forming a 2cm diameter defect on the back of the rat and then examining the change of the size of the wound according to time, The average value of one value is shown in Fig.
[식 1][Equation 1]
Wound size change(%) = 
Wo : 창상 유발 직후 창상부 면적Wo: Area above the window immediately after wounding
Wi : 측정일 창상부 면적Wi: Top area of measurement window
도 4를 통하여 알 수 있는 바와 같이, PDRN이 첨가된 실시예 1의 창상피복재가 비교예 1에 비하여 조직재생력이 강화됨을 확인할 수 있었다. As can be seen from FIG. 4, it was confirmed that the wound dressing of Example 1 to which PDRN was added had enhanced tissue regeneration ability as compared with Comparative Example 1.
Claims (7)
상기 PDRN은
정제되지 않은 PDRN에 증류수를 첨가하는 단계;
500kDa 이하의 PDRN이 여과될 수 있는 막을 통과시키는 1차 정제단계;
상기 1차 정제된 PDRN에 증류수를 첨가하는 단계;
200kDa 이하의 PDRN이 여과될 수 있는 막을 통과시키는 2차 정제단계;
상기 2차 정제단계에서 정제되지 않은 PDRN과 불순물을 분리하는 단계;
를 포함하는 막분리법에 의해 수득되며 분자량이 350±150kDa인 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재.
Chitosan hydrogel, PDRN and an additive,
The PDRN
Adding distilled water to the unpurified PDRN;
A first purification step of passing a membrane through which a PDRN of 500 kDa or less can be filtered;
Adding distilled water to the first purified PDRN;
A second purification step of passing a membrane through which a PDRN of less than or equal to 200 kDa can be filtered;
Separating impurities from the PDRN not purified in the second purification step;
, And has a molecular weight of 350 + - 150 kDa. The wound dressing with enhanced regrowth of tissue containing chitosan hydrogel and PDRN.
상기 키토산하이드로겔은 가교제를 하지 않고 자가가교를 진행하는 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재.
The method according to claim 1,
The chitosan hydrogel and the PDRN-containing wound dressing reinforced with tissue regeneration ability, wherein the chitosan hydrogel is self-crosslinked without a cross-linking agent.
상기 1차 정제단계 및 2차 정제단계는 3 내지 4회 반복 진행하는 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재.
The method according to claim 1,
Wherein the first purification step and the second purification step are repeated three to four times. The wound dressing with chitosan hydrogel and PDRN containing tissue regenerating power is enhanced.
상기 첨가제는 PDRN의 용출을 도와주는 것으로 토코페롤인 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재.
The method according to claim 1,
Wherein the additive is tocopherol which assists elution of the PDRN, the chitosan hydrogel and the PDRN.
상기 창상피복재는 유착방지제, 연골재생주사, 필러, 마스크팩 등의 제형으로 제조될 수 있는 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재.
The method according to claim 1,
Wherein the wound dressing can be manufactured by a formulation such as an anti-adhesion agent, a cartilage regeneration injector, a filler, a mask pack, etc., and a tissue regenerative wound dressing containing the chitosan hydrogel and the PDRN.
The wound dressing according to any one of claims 1 to 4 may be applied by a spraying type coating agent, wherein the spraying type coating agent is a mixture of ethanol and ethyl acetate in a ratio of 1: 2 to nitrocellulose in an amount of 5 to 20 wt. % Solubilized solution containing chitosan hydrogel and PDRN.
500kDa 이하의 PDRN이 여과될 수 있는 막을 3 내지 4회 통과시키는 1차 정제단계;
상기 1차 정제된 PDRN에 증류수를 첨가하는 단계;
200kDa 이하의 PDRN이 여과될 수 있는 막을 3 내지 4회 통과시키는 2차 정제단계;
상기 2차 정제단계에서 분리된 200kDa 미만의 PDRN을 제거하는 단계;
상기 2차 정제단계에서 정제되지 않은 PDRN과 불순물을 분리하는 단계;
를 포함하는 막분리법에 의해 분자량이 350±150kDa인 PDRN을 수득하는 단계; 및
키토산하이드로겔을 혼합하는 단계를 포함하는 것을 특징으로 하는, 키토산하이드로겔 및 PDRN을 함유하는 조직재생력이 강화된 창상피복재의 제조방법.
Adding distilled water to the unpurified PDRN;
A first purification step in which the PDRN of 500 kDa or less is passed through the membrane to be filtered three to four times;
Adding distilled water to the first purified PDRN;
A second purification step in which a PDRN of 200 kDa or less is passed through a membrane that can be filtered three to four times;
Removing the PDRN of less than 200 kDa separated in the second purification step;
Separating impurities from the PDRN not purified in the second purification step;
To obtain a PDRN having a molecular weight of 350 +/- 150 kDa; And
A method for manufacturing a wound dressing with enhanced regrowth of tissue containing chitosan hydrogel and PDRN, comprising the step of mixing chitosan hydrogel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160160121A KR20180060542A (en) | 2016-11-29 | 2016-11-29 | Wound dressing with chitosan hydrogel and pdrn and a dressing therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160160121A KR20180060542A (en) | 2016-11-29 | 2016-11-29 | Wound dressing with chitosan hydrogel and pdrn and a dressing therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180060542A true KR20180060542A (en) | 2018-06-07 |
Family
ID=62621835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160160121A KR20180060542A (en) | 2016-11-29 | 2016-11-29 | Wound dressing with chitosan hydrogel and pdrn and a dressing therefor |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180060542A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214694A (en) * | 2020-03-31 | 2020-06-02 | 山东大鱼生物技术有限公司 | Dressing with functions of stopping bleeding and accelerating wound healing and preparation method thereof |
| KR20230054144A (en) | 2021-10-15 | 2023-04-24 | 주식회사 영우 | Water-soluble adhesive dressing material |
| KR102658481B1 (en) * | 2023-05-15 | 2024-04-17 | 권한진 | Filler composition for chondrocyte differentiation and collagan activity and manufacturing method thereof |
-
2016
- 2016-11-29 KR KR1020160160121A patent/KR20180060542A/en not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214694A (en) * | 2020-03-31 | 2020-06-02 | 山东大鱼生物技术有限公司 | Dressing with functions of stopping bleeding and accelerating wound healing and preparation method thereof |
| CN111214694B (en) * | 2020-03-31 | 2022-04-22 | 山东大鱼生物技术有限公司 | Dressing with functions of stopping bleeding and accelerating wound healing and preparation method thereof |
| KR20230054144A (en) | 2021-10-15 | 2023-04-24 | 주식회사 영우 | Water-soluble adhesive dressing material |
| KR102658481B1 (en) * | 2023-05-15 | 2024-04-17 | 권한진 | Filler composition for chondrocyte differentiation and collagan activity and manufacturing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108014366B (en) | Marine biological material composite hydrogel dressing and preparation method thereof | |
| FI104148B (en) | Process for preparing a hydrated self-supporting gel membrane | |
| EP1696971B1 (en) | Therapeutically active wound dressings, production thereof, and use of the same | |
| Lima et al. | Skin wounds, the healing process, and hydrogel-based wound dressings: A short review | |
| Yan et al. | Oxidized Bletilla rhizome polysaccharide-based aerogel with synergistic antibiosis and hemostasis for wound healing | |
| CN109248333B (en) | Medical dressing for resisting bacteria and promoting wound healing and preparation method and application thereof | |
| CN110237054B (en) | Scar repairing material and preparation method thereof | |
| KR20180060542A (en) | Wound dressing with chitosan hydrogel and pdrn and a dressing therefor | |
| Terezaki et al. | Ulvan/gelatin-based nanofibrous patches as a promising treatment for burn wounds | |
| JP2022547185A (en) | Wound-healing composition containing metal-organic framework | |
| KR20020000580A (en) | Wound dressing containing a chitosan/PVA (polyvinylalcohol) hydrogel and process for preparing thereof | |
| Valipour et al. | Preparation and characterization of wound healing hydrogel based on fish skin collagen and chitosan cross-linked by dialdehyde starch | |
| CN112891615B (en) | Liquid adhesive bandage and preparation method thereof | |
| CN1194777C (en) | Artificial skin and its prepn and use | |
| CN111643723B (en) | Liquid dressing containing icodextrin | |
| US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| CN111214694A (en) | Dressing with functions of stopping bleeding and accelerating wound healing and preparation method thereof | |
| Shukla et al. | Electrospun nanofibers for wound healing | |
| KR101576244B1 (en) | aloin loaded wound dressing composition based on hydrogel and manufacturing method thereof | |
| Ketan et al. | Assessing the efficacy of haemostatic dressing Axiostat® in trauma care at a tertiary care hospital in India: A comparison with conventional cotton gauze | |
| Khalid et al. | Polysaccharide composites as a wound-healing sponge | |
| Alven et al. | Fabrication of hybrid nanofibers from biopolymers and poly (vinyl alcohol)/poly (ε-caprolactone) for wound dressing applications, Polymers (Basel) 2021, 13 (13) | |
| CN108404193B (en) | Bletilla striata hemostatic bandage product and preparation method thereof | |
| Campelo et al. | Agaricus blazei Murill extract‐loaded in alginate/poly (vinyl alcohol) films prepared by Ca 2+ cross‐linking for wound healing applications. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E601 | Decision to refuse application |